This website is best viewed using the vertical display on your mobile device.
SPRYCEL® (dasatinib) is indicated for the treatment of adult patients with:
SPRYCEL® is indicated for the treatment of pediatric patients 1 year of age and older with:
cCCyR† rates vs imatinib by Year 1 and Year 51
Dasatinib does not appear to be active against the T315I mutation, based on in vitro data.1
In newly diagnosed chronic phase CML patients:
Sprycel has been on the market for
Dasatinib (SPRYCEL) is a National Comprehensive Cancer Network® (NCCN®) Category 1 preferred treatment recommendation regardless of risk score.3¶
¶NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
cCCyR=confirmed complete cytogenetic response; CI=confidence interval; MMR=major molecular response.
*Inclusive of cCCyR in newly diagnosed adult patients with CP Ph+ CML by 1 and 5 years.
†Confirmed CCyR (cCCyR) was defined as CCyR (0% Ph+ metaphases) on 2 consecutive occasions at least 28 days apart.1,2
‡Adjusted for Hasford score and indicated statistical significance at a predefined nominal level of significance.1
||MMR (at any time) defined as BCR-ABL ratios of ≤0.1% by RQ-PCR in peripheral blood samples standardized on the International Scale. These are cumulative rates representing minimum follow-up for the time frame specified.1